The Readout Loud

STAT
The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

  1. -1 DIA

    342: FDA cuts, zombie biotechs, and too much weight loss?

    Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater and greater weight loss from obesity drugs, along with developments at Solid Biosciences and federal job cuts.

    41 min

  2. 13/02

    341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

    We bring on biotech reporter Jonathan Wosen to discuss the NIH's decision to dramatically cut funding for overhead costs paid to research institutions and the potential implications for U.S. biomedical innovation. We also chat with health tech reporter Brittany Trang about the claims that two drug developers, Absci and Generate:Biomedicines, have made about the capabilities of their artificial intelligence technologies, and why some experts are skeptical.

    27 min

  3. 6/02

    340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

    We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.

    35 min

  4. 30/01

    339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

    Our colleague Rachel Cohrs Zhang joins us to break down RFK Jr.’s confirmation hearings, including some contentious questions about vaccines and autism from Sens. Bill Cassidy (R-La.) and Bernie Sanders (I-Vt.). But first, we chat about Akero Therapeutics and the results reported this week from a study of its experimental drug that showed, for the first time, reversal of cirrhosis in patients with severe MASH. We critique that Hims & Hers commercial. And lastly, we talk about a new fund from biotech VC Curie.Bio and the money it’s invested in a still-stealthy gene therapy company trying to tackle ALS.

    34 min

  5. 23/01

    338: Chinese biotechs, a WHO departure, and post-JPM thoughts

    We go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs and a surprise run-in with a past cohost. Then, STAT's infectious disease reporter Helen Branswell joins us to explain the implications of Trump's decision to pull the U.S. out of the WHO.

    33 min

  6. 15/01

    337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

    We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effects of Medicare's drug price negotiation, Lilly's recent disappointing guidance, pricing of the company's obesity medication Zepbound, and more. We also discuss the latest news from the J.P. Morgan conference, including M&A deals, licensing of drugs from China, and the broader sentiment in the industry.

    59 min

  7. 9/01

    336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

    We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.

    33 min

  8. 19/12/2024

    335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

    STAT's FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump's nominee for FDA commissioner. Then, we discuss the results of Vertex's latest pain drug trial, the medication launches to watch in 2025, and present our burning questions for the biopharma industry.

    34 min
Ver tudo (346)

Apresentadores e convidados

Sobre

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Informação

  • Autoria
    STAT
  • Anos em atividade
    2018 - 2025
  • Episódios
    346
  • Classificação
    Para todos
  • Copyright
    © All rights reserved
  • Site do programa
    The Readout Loud

Talvez também goste

Para ouvir os episódios explícitos, inicie sessão.

Mantenha-se atualizado sobre este programa

Inicie sessão ou efetue o registo para seguir programas, guardar episódios e obter as atualizações mais recentes.
Selecione um país ou uma região

África, Médio Oriente e Índia

Ásia‑Pacífico

Europa

América Latina e Caraíbas

Estados Unidos e Canadá